Yonsei Med J.  2007 Dec;48(6):994-1000. 10.3349/ymj.2007.48.6.994.

High-Dose Terazosin Therapy (5mg) in Korean Patients with Lower Urinary Tract Symptoms with or without Concomitant Hypertension: A Prospective, Open-Label Study

Affiliations
  • 1Department of Urology, Seoul National University College of Medicine, Seoul, Korea. randyku@hanmail.net
  • 2Department of Urology, Seoul Veterans Hospital, Seoul, Korea.

Abstract

PURPOSE: We determined the efficacy and safety of a relatively high dose of terazosin (5mg) in Korean patients with lower urinary tract symptoms (LUTS), with or without concomitant hypertension. MATERIALS AND METHODS: From July to December 2006, 200 men who consecutively presented with LUTS were prospectively studied. Eight weeks after treatment, blood pressure (BP), uroflowmetry, and International Prostate Symptom Score (I-PSS) were assessed. For analysis purposes, patients were stratified according to concomitant hypertension. Of the 200 patients, 173 completed the scheduled eight-week treatment period. RESULTS: At baseline, no differences were evident in the two groups in terms of I-PSS, Qmax, PVR and BP. After eight weeks of treatment-although I-PSS and uroflowmetry parameters were not significantly different in the two groups-systolic and diastolic BP in the non-hypertensive control group were higher than in the hypertensive group (p= 0.001 and p=0.0100, respectively). Changes in I-PSS, uroflowmetry parameters, and BPs measured at week eight post- treatment commencement did not significantly differ between the two groups. Moreover, the addition of 5mg of terazosin to antihypertensives did not cause a significant reduction in either systolic or diastolic BP in either group. CONCLUSION: Adding terazosin to existing antihypertensive regimens did not seem to increase the incidence of adverse events. Our findings suggest that 5mg terazosin is effective and that it has an acceptable safety profile as an add-on therapy for patients with LUTS and concomitant hypertension.

Keyword

Hypertension; prostate; lower urinary tract symptoms; terazosin

MeSH Terms

Adrenergic alpha-Antagonists/adverse effects/therapeutic use
Aged
Asian Continental Ancestry Group
Blood Pressure/drug effects
Humans
Hypertension/complications/*drug therapy/physiopathology
Korea
Male
Middle Aged
Prazosin/adverse effects/*analogs & derivatives/therapeutic use
Prospective Studies
Prostate/drug effects/pathology
Treatment Outcome
Urodynamics/drug effects
Urologic Diseases/complications/*drug therapy/ethnology

Reference

1. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995. 168:7–12.
2. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol. 2003. 10:569–575.
Article
3. Tanaka Y, Masumori N, Itoh N, Sato Y, Takahashi A, Ogura H, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol. 2002. 167:2492–2495.
Article
4. Okada H, Kamidono S, Yoshioka T, Okuyama A, Ozono S, Hirao Y, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 2000. 85:676–681.
Article
5. Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997. 80:606–611.
Article
6. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992. 148:1467–1474.
Article
7. Kumamoto Y, Tsukamoto T, Yachiku S. Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (II): Double-blind comparative study compared with placebo. Hinyoukigeka. 1992. 5:823–840.
8. Nakamura S, Ishiyama S, Kobayashi Y, Tokue A. Clinical effect of terazosin hydrochloride on benign prostatic hypertrophy: examination by whole day uroflowmetry. Jpn J Urol Surg. 1992. 5:447–451.
9. Ebihara A, Kondo K, Ohashi K. Pharmacokinetics and pharmacological properties of terazosin hydrochloride, a new α1-blocker: a single dose study on Japanese healthy subjects. Clin Med Pharmaceut. 1987. 3:667–679.
10. Stone EA, Zhang Y, Rosengarten H, Yeretsian J, Quartermain D. Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice. Neuroscience. 1999. 94:1245–1252.
Article
11. Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol. 1994. 261:59–64.
Article
12. Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther. 1999. 21:1732–1748.
Article
13. Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology. 1999. 54:81–85.
Article
14. Lowe F, Tuttle J, Marks S, Steidle C, Jacobs T, Padley RJ. The HYCAT investigator group. Blood pressure effects of men with prostatism concurrently treated with anti-hypertensives and terazosin. J Urol. 1995. 153:176. (272A).
15. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology. 1994. 44:46–51.
Article
16. Lenz ML, Pool JL, Laddu AR, Varghese A, Johnston W, Taylor AA. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995. 8:133–145.
Article
17. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol. 2000. 163:1134–1137.
Article
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr